Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IPSCBullishIndustry Newsnews

High materiality7/10

Century Therapeutics advances CNTY-813 toward IND with strong nonclinical data

Oct 2, 2026, 8:16 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive nonclinical data and a clear IND timeline provide near-term catalysts; historical biotech clean-room data and IND timing gaps have driven upside when data readouts align with timelines, though execution and regulatory outcomes remain risk factors.

AI summary

What happened, with direct paths to the underlying reporting

Century Therapeutics reports CNTY-813 Allo-Evasion 5.0 nonclinical data showing sustained glycemic control in mice, successful engraftment, and manufacturing consistency across five clinical-scale batches. IND filing remains on track for 4Q2026 with initial safety/early efficacy data expected in 2H2027, potentially advancing IPSC-derived islet therapy for type 1 diabetes.

CNTY-813 IND on track for 4Q26; 2H27 initial data planned.
Allo-Evasion 5.0 enables immune evasion and glycemic control in mice; engraftment shown.
Five clinical-scale CNTY-813 batches produced; 29-day process meets purity criteria.
Nonclinical data show sustained glycemic control and successful liver engraftment in animals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.